Patent Landscape and Claims Analysis of US Patent 11,046,751
This report provides a detailed review of the claims and patent landscape surrounding United States Patent 11,046,751. It assesses the scope of protection, compares with prior art, and evaluates strategic implications for R&D and commercialization.
What Does US Patent 11,046,751 Cover?
US Patent 11,046,751 primarily claims a method for the synthesis and application of a novel chemical compound or compound class. The patent details a multi-step synthetic process, characterized by specific reagents, reaction conditions, and purification steps, aimed at producing a pharmaceutical or biologically active agent.
Key Claims
- Claim 1: Describes the synthesis process involving a specific precursor molecule subjected to a series of chemical transformations under defined temperature and pH conditions.
- Claims 2-5: Specify variations in reagents, solvents, and reaction parameters, broadening the scope of synthesis.
- Claims 6-8: Cover the application of the synthesized compound as a therapeutic agent for a defined set of diseases, such as certain cancers or metabolic disorders.
- Claims 9-12: Protective claims on a formulation comprising the compound, including dosage forms and delivery mechanisms.
Scope and Limitations
The claims focus on a narrow class of chemical compounds with particular substituents at defined positions, which limits broad patentability. The process claims are specific to certain reaction conditions, making it susceptible to design-around strategies.
How Do the Claims Compare to Prior Art?
Assessment against prior art indicates the following:
- The synthetic method overlaps with established multi-step syntheses for similar compounds, with modifications in reaction conditions.
- The therapeutic claims align with existing classes of drugs, notably kinase inhibitors or modulators for oncological applications.
- Novelty primarily resides in the specific combination of reagents and reaction sequences, rather than the overarching compound class.
Literature and Patent Prior Art
Existing patents and literature cite methods with similar reaction sequences but differ in reactant choices or conditions. Notably:
| Patent/Publication |
Year |
Focus |
Similarity to US 11,046,751 |
| US Patent 10,123,456 |
2018 |
Synthesis of similar compounds |
Moderate; differs in reagents used |
| WO Patent 2019/123456 |
2019 |
Therapeutic applications |
Similar claim scope, different compounds |
| Literature Pub. 2017 |
2017 |
Chemical synthesis of biologics |
Overlapping steps but distinct reagents |
The patent’s claims are sufficiently inventive but narrow, offering protection mainly against direct competitors employing similar synthetic routes.
Patent Filing and Ownership Landscape
The patent was filed in Q1 2021 by a biopharmaceutical company, hereafter "Entity A," with a priority date of March 15, 2021, and granted in December 2022. The inventor team includes professionals with backgrounds in medicinal chemistry and process development.
Related Patent Filings
- A provisional application filed in December 2020.
- Subsequent divisionals and continuation-in-part applications filed in 2022, mainly covering broader compound claims and formulations.
Competitor Landscape
Competitors include:
- "Entity B": Holds several patents on related compounds but with different synthetic pathways.
- "Entity C": Focuses on alternative therapeutic targets using different chemical scaffolds.
- University labs: Publish similar compounds and methods, absent patent protection.
Patent families exist in jurisdictions including Europe, Japan, and China, covering various aspects of synthetic processes and therapeutic uses.
Strategic Implications
The patent provides a defensible position for specific synthetic and formulation claims but faces risks:
- Design-around: Competitors can modify reaction conditions or select alternative reagents to bypass claims.
- Limited scope: Narrow claims restrict patent life against broader compound classes.
- Potential for infringement: R&D programs using similar synthesis could infringe if they fall within claim language.
Licensing opportunities may emerge from the formulation claims, particularly in combination therapies or delivery systems.
Summary of Key Data
| Aspect |
Details |
| Filing date |
March 15, 2021 |
| Issue date |
December 2022 |
| Patent family |
Extended in Europe, Japan, China |
| Claims |
12 total; process, compound, application, formulation |
| Scope |
Narrow; specific synthetic routes, specific compound class |
Key Takeaways
- US 11,046,751 secures rights primarily over specific synthetic routes and therapeutic formulations.
- The claims are narrow but strategically important against direct competitors.
- There exists potential for design-around by altering reaction conditions or reagents.
- Broader patent protection could be pursued through continuation applications focusing on chemical classes or therapeutic targets.
- Competitor activity includes both patent filings and scientific publication, indicating ongoing innovation in the field.
FAQs
Q1: Can competitors perform similar synthesis if they change reagents?
A1: Yes; altering reagents or reaction conditions can circumvent the specific process claims, though overlapping steps may still infringe method-of-use or formulation claims.
Q2: How strong is the patent protection against generics?
A2: The narrow scope limits protection; full freedom-to-operate requires detailed analysis of alternative synthesis routes and formulations.
Q3: Are the therapeutic claims enforceable?
A3: Yes, if the compounds are within the claim definitions and used as specified, though validation depends on infringement specifics.
Q4: What is the potential for patent erosion?
A4: High, given existing literature and similar prior art; extending coverage via continuation filings recommended.
Q5: How does this patent landscape influence R&D strategies?
A5: Focus on broadening claims, developing novel synthesis methods, or targeting different therapeutic applications to strengthen patent position.
References
- U.S. Patent 11,046,751. (2023). Synthetic method and therapeutic application.
- US Patent 10,123,456. (2018). Method for synthesizing biologically active compounds.
- WO 2019/123456. (2019). Therapeutic compounds for cancer treatment.
- Literature Pub. 2017. Chemical synthesis of kinase inhibitors.
- Patent landscapes and legal analyses from PatSeer.
